

Cover Story
Relying largely on maturing data from the European trials of screening for prostate cancer, the U.S. Preventive Services Task Force has given a better grade—a “C”—to screening for prostate cancer.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Trump imposes up to 100% tariff on some brand name pharmaceutical companies
- Michael Bishop, Nobel-winning cancer researcher, dies at 90
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case




















